Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–165 of 165 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Conversion Clear all
Completed Phase 3 Interventional Results available

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

NCT01411137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • Sunnyvale, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 23, 2026, 5:18 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

NCT01737879
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide, Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 23, 2026, 5:18 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

NCT02302989
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

NCT01300728
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
NewGam 10% IVIG, Placebo
Drug · Other
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 23, 2026, 5:18 PM EDT
Terminated Phase 4 Interventional Results available

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255
View directory record Official record
Conditions
Kidney Transplant, Delayed Graft Function
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Not applicable Interventional

The Impact of Social Proximity on Conversion to Generic Prescription Medications

NCT01251419
View directory record Official record
Conditions
Conversion From Brand Name to Generic Medication
Interventions
Social Proximity and Conversion to Generic Medications
Other
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 23, 2026, 5:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin

NCT01053286
View directory record Official record
Conditions
Dysphagia, Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 23, 2026, 5:18 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

NCT00086346
View directory record Official record
Conditions
Liver Transplantation
Interventions
Sirolimus (Rapamune), Cyclosporine or Tacrolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
13 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
10
States / cities
San Francisco, California • Tampa, Florida • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2010 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

NCT00126074
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Honolulu, Hawaii • Tullahoma, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 23, 2026, 5:18 PM EDT
Withdrawn Not applicable Interventional

SAINT for Treatment of Preoperative Depression to Reduce Opioid Use Following Arthroplasty

NCT04195308
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC, Open label TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Not applicable Interventional Results available

Sirolimus Conversions in African-American Renal Transplant Recipients

NCT01005706
View directory record Official record
Conditions
Absence; Kidney
Interventions
rapamune, mycophenolate mofetil and steroid, tacrolimus, sirolimus and steroid
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 23, 2026, 5:18 PM EDT
Withdrawn Not applicable Interventional

Demonstrating Efficacy of JOGO for the Treatment of Tremor

NCT06346873
View directory record Official record
Conditions
Functional Neurological Disorder
Interventions
JOGO
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 23, 2026, 5:18 PM EDT
Recruiting Early Phase 1 Interventional

Accelerated TMS for Seizure-Type Functional Neurologic Disorders

NCT07059325
View directory record Official record
Conditions
Functional Neurological Symptom Disorder, Functional Seizures
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 5:18 PM EDT
Completed No phase listed Observational

Myfortic Conversion Trial in OLT Recipients With GI Intolerance

NCT00619216
View directory record Official record
Conditions
GI Disturbance
Interventions
Mycophenolic Acid (Myfortic)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2011 · Synced Oct 23, 2026, 5:18 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082571
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 23, 2026, 5:18 PM EDT
Completed No phase listed Observational

Gastric Bypass After Previous Anti-reflux Surgery

NCT01041105
View directory record Official record
Conditions
Clinically Severe Obesity, Gastroesophageal Reflux Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2010 · Synced Oct 23, 2026, 5:18 PM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00492999
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

NCT01791491
View directory record Official record
Conditions
Kidney Transplant
Interventions
Belatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 23, 2026, 5:18 PM EDT